Skip to content

Gender Disparity and Hormones in Cystic Fibrosis

Gender Disparity and Hormones in Cystic Fibrosis

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02036879
Enrollment
55
Registered
2014-01-15
Start date
2014-02-28
Completion date
2018-08-31
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis (CF)

Keywords

Cystic Fibrosis, Loestrin, Hormone

Brief summary

The objective of this study is to investigate the impact of hormones on lung disease in Cystic Fibrosis (CF) patients. Due to improved therapies, CF patients are living longer and healthier lives than they did 20 years ago. However, females have been shown to have a survival disadvantage. The median life expectancy is 33 in women and 37 in men with CF. The hypothesis is that estrogen and/or progesterone negatively impact lung health in CF. Therefore, understanding the impact of sex hormones (including the use of birth control pills) on the disease process is increasingly important. The purpose of this study is to determine if lung function, respiratory symptoms, or various markers of lung health change during different phases of the natural ovulatory cycle in order to understand if estrogen or progesterone hormones are impacting the disease relative to fluctuations in men with stable testosterone levels. The research objectives of this project are to: * Determine if lung function, respiratory symptoms, or various markers of lung health change during different hormonal phases of the ovulatory cycle in women. * Determine if men change lung function, respiratory symptoms, or various markers of lung health over time. * Determine if oral contraceptive pills in women stabilize fluctuations in symptoms and improve lung health.

Interventions

DRUGLoestrin (norethindrone acetate and ethinyl estradiol)

This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.

Sponsors

University of Texas Southwestern Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and female cystic fibrosis patients * Must be greater than or equal to 18 years of age. * All subjects must understand and sign the informed consent. * Subjects must have the ability to read and write in English. * Female subjects starting this study must be willing to use a double barrier method of birth control (such as condom or diaphragm) used with a spermicide (a substance that kills sperm), while participating in the study.

Exclusion criteria

for Main Study: * Women who are pregnant, breast feeding, or who have had an oophorectomy. * Women who have received a hormone contraceptive injection (such as Depo Provera) within the last 3 months.

Design outcomes

Primary

MeasureTime frame
Change in percent predicted forced expiratory volume in 1 second (FEV1)Through Visit 5, if applicable (or approximately 3 months)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026